ACHIEVING COMPREHENSIVE DISEASE CONTROL IN LONG-STANDING OR EARLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ADALIMUMAB PLUS METHOTREXATE VERSUS METHOTREXATE ALONE

被引：0
|
作者：
Keystone, E. C. [1 ]
Breedveld, F. C. [2 ]
van der Heijde, D. [2 ]
van Vollenhoven, R. F. [3 ]
Florentinus, S. [4 ]
Faccin, F. [5 ]
Liu, S. [5 ]
Kupper, H. [6 ]
Kavanaugh, A. F. [7 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Leiden Univ Med Ctr, Leiden, Netherlands
[3] Karolinska Inst, Stockholm, Sweden
[4] AbbVie, Rungis, France
[5] AbbVie Inc, N Chicago, IL USA
[6] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
[7] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：228 / 228
页数：1
相关论文
共 50 条
  • [31] Radiographic inhibition of structural damage sustained in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (HUMIRA®) plus methotrexate.
    Keystone, EC
    Kavanaugh, AF
    Sharp, JT
    Spencer-Green, GT
    Perez, JL
    Sasso, EH
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S189 - S189
  • [32] EMPLOYABILITY-ADJUSTED-LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH GOLIMUMAB PLUS METHOTREXATE OR METHOTREXATE ALONE
    Han, Chenglong
    Gathany, Tim
    Tandon, Neeta
    Hsia, Elizabeth
    RHEUMATOLOGY, 2012, 51 : 172 - 172
  • [33] EMPLOYABILITY-ADJUSTED-LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH GOLIMUMAB PLUS METHOTREXATE OR METHOTREXATE ALONE
    Han, C.
    Gathany, T.
    Tandon, N.
    Hsia, E.
    VALUE IN HEALTH, 2011, 14 (03) : A131 - A132
  • [34] Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial
    Sode, Jacob
    Krintel, Sophine B.
    Carlsen, Anting Liu
    Hetland, Merete L.
    Johansen, Julia S.
    Horsley-Petersen, Kim
    Stengaard-Pedersen, Kristian
    Ellingsen, Torkell
    Burton, Mark
    Junker, Peter
    Ostergaard, Mikkel
    Heegaard, Niels H. H.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (01) : 53 - 61
  • [35] Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
    Smolen, Josef S.
    van Vollenhoven, Ronald F.
    Florentinus, Stefan
    Chen, Su
    Suboticki, Jessica L.
    Kavanaugh, Arthur
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (11) : 1566 - 1572
  • [36] Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis
    Emery, Paul
    Genovese, Mark C.
    van Vollenhoven, Ronald
    Sharp, John T.
    Patra, Kaushik
    Sasso, Eric H.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (07) : 1429 - 1441
  • [37] Treatment Outcomes Based on Methotrexate Dose Range in Patients with Rheumatoid Arthritis Receiving Etanercept Plus Methotrexate Versus Methotrexate Alone.
    Fleischmann, Roy
    Koenig, Andrew S.
    Pedersen, Ronald
    Ferdousi, Tahmina
    Bananis, Eustratios
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S168 - S168
  • [38] Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis
    Yount, S.
    Sorensen, M. V.
    Cella, D.
    Sengupta, N.
    Grober, J.
    Chartash, E. K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (06) : 838 - 846
  • [39] Early rheumatoid arthritis: combination therapy of doxycycline plus methotrexate versus methotrexate monotherapy
    Graciela S Alarcón
    Nature Clinical Practice Rheumatology, 2006, 2 : 296 - 297
  • [40] Early rheumatoid arthritis:: combination therapy of doxycycline plus methotrexate versus methotrexate monotherapy
    Alarcón, GS
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (06): : 296 - 297
12345